In Vivo Synergy Between 6β-Amidinopenicillanic Acid Derivatives and Other Antibiotics
Author(s) -
E. Grunberg,
Roy Cleeland,
G. Beskid,
W. F. DeLorenzo
Publication year - 1976
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.9.4.589
Subject(s) - microbiology and biotechnology , cefazolin , ampicillin , antibiotics , gentamicin , enterobacter , carbenicillin , benzylpenicillin , gram negative bacteria , enterobacter aerogenes , biology , klebsiella , in vivo , providencia , bacteria , gram positive bacteria , escherichia coli , penicillin , biochemistry , genetics , gene
Both an oral and a parenteral form of a 6β-amidinopenicillanic acid derivative were found to have appreciable activity against gram-negative bacteria and poor activity against gram-positive bacteria in vivo. When administered orally or parenterally, definite synergy was demonstrated between the amidinopenicillins and ampicillin, amoxicillin, benzylpenicillin, cefazolin, or carbenicillin in infections with a number of gram-negative bacteria, includingKlebsiella, Enterobacter, Escherichia, Proteus, Salmonella , andHaemophilus species in mice. Synergy was also observed between the parenteral amidinopenicillin and benzylpenicillin in theStaphylococcus aureus infection but not in infections with other gram-positive organisms. No synergy was demonstrated between the parenteral amidinopenicillin and erythromycin or oxytetracycline in infections with gram-positive or gram-negative organisms. Synergy between the parenteral amidinopenicillin and gentamicin was observed only in the case ofEscherichia coli .
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom